Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Anilkumar Raghavan | Chief Executive Officer | -- | -- | 1968 |
| Mr. Anup Rathi | Chief Financial Officer | -- | -- | -- |
| Dr. Nitin Dharmadhikari | Chief Operating Officer | -- | -- | 1962 |
| Mr. Jaydeep Issrani | Senior General Manager of Business Development, Corporate Communication & Investor Relations | -- | -- | -- |
| Ms. Kajal K. Damania | Company Secretary & Compliance Officer | -- | -- | -- |
| Ms. Shanta Gupta | Chief Human Resource Officer | -- | -- | -- |
| Mr. Siu-Long Yao | Head Clinical Development | -- | -- | -- |
| Dr. Nitin K. Damle Ph.D. | Chief Innovation Officer | -- | -- | -- |
| Dr. Yashoraj Zala | Head of Drug Delivery Systems | -- | -- | -- |
| Dr. Vikram K. Ramanathan | Head of Preclinical Development | -- | -- | -- |
Sun Pharma Advanced Research Company Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 409
Description
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Corporate Governance
Upcoming Events
May 22, 2025 at 10:59 AM UTC - May 26, 2025 at 12:00 PM UTC
Sun Pharma Advanced Research Company Limited Earnings Date
Recent Events
Recent Events Information Not Available